Introduction
The c-Src proto-oncogene is the cellular homolog of the viral oncogene v-Src of Rous sarcoma virus (RSV), which was the first identified retroviral oncogene protein. c-Src is a non-receptor tyrosine kinase that is involved in a wide range of cellular functions including migration, invasion and adhesion. Elevated Src activity promotes oncogenic transformation [1] . The in vitro transforming capacity of activated Src kinase was originally demonstrated in RSV-infected (and thereby v-Src-expressing) chicken cells [2] . Src kinase-induced transformation also occurs in mammalian cells, and has been demonstrated by ectopic expression of v-Src in mouse fibroblasts [3] . In vitro studies with the human non-transformed epithelial breast cell line MCF-10A [4] have shown that activation of Src kinase activity leads to transformation in vitro, and tumor formation in nude mice [5] [6] [7] . Despite its known role in promoting cellular transformation, many of the functions of Src at the molecular level remain unclear [1] .
Known targets of Src kinase include focal adhesion proteins, adaptor proteins, cell-cycle regulators and transcription factors. Src family kinases (SFKs) have been shown to modulate cell-cell and cell-matrix interactions, and to promote the expression of matrixdegrading enzymes. The c-Src protein is regulated by reversible phosphorylation of tyrosine residues Y416 and Y527 (numbering according to v-Src) and by protein-protein interactions through its Src homology (SH) domains SH2 and SH3 [1] . Phosphorylation of Y527 inactivates the kinase activity of c-Src by inducing a compact autoinhibitory protein conformation, while its dephosphorylation leads to an open active conformation [8, 9] . Y527 is phosphorylated by the non-receptor tyrosine kinases C-terminal Src kinase and C-terminal Src kinase-homologous kinase [10] . Dephosphorylation of Y527 is catalyzed by several protein tyrosine phosphatases such as protein tyrosine phosphatase a [11] and SH2 domain-containing phosphatases 1 [12] and 2 [13] . Y416 is an autophosphorylation site whose phosphorylation is required for optimal c-Src kinase activity [14] . Moreover, various c-Src-interacting proteins may modulate its kinase activity non-enzymatically, such as focal adhesion kinase (FAK) [15] and SH2 domain-containing phosphatase 2 [16] , which bind to the SH2 and SH3 domains, respectively, leading to increased kinase activity.
A conserved C-terminal hydrophobic motif, GENL, is shared by a number of ubiquitously expressed SFKs, including Src, Yes and Fyn. In contrast, SFKs lacking this motif, such as Lyn, Lck, Hck and Blk, are mainly expressed in non-adherent hematopoietic cells [17] . Thus, the C-terminus of c-Src appears to be relevant for adherence, and its absence, for instance in the v-Src protein, appears to contribute to non-adherent phenotypes of cells. Therefore, we suspected a possible role for the absent C-terminus in migration and invasion. The C-terminal GENL motif of c-Src has been described as binding motif for PDZ (postsynaptic density 95/discs large/zonula occludens-1) domains, and the C-terminal hydrophobic leucine residue is crucial for this interaction [17] . By substituting this single amino acid by alanine, to create a protein herein referred to c-Src(mt), we demonstrated loss of binding to PDZ domains, which are characteristic of many tumor suppressor proteins in MCF-10A and other cell lines. c-Src-interacting PDZ proteins include the tumor suppressor AF-6 (Afadin), the Membrane Protein Palmitoylated 2 (MPP2), a homolog of the Drosophila tumor suppressor Discs large (Dlg) and LNX1 (Ligand-of-Numb protein X1) [17] [18] [19] [20] . Disruption of these interactions by alteration of the C-terminal motif led to constitutive activation and elevated kinase activity compared with wild-type c-Src protein with the intact GENL sequence [17] [18] [19] [20] . We previously noted that expression of c-Src(mt) changed the cellular morphology more than expression of c-Src(wt). Such changes included impaired cell polarization and disorganization of the cytoskeleton in MCF-10A cells, associated with increased cellular transformation, as characterized by in vitro assays [17, 19] . Ectopic expression of c-Src(mt) in MCF-10A cells also led to increased colony formation in soft agar, and foci formation on normal cell culture plates, as well as elevated invasion of Matrigel test systems [17] . Moreover, c-Src (mt)-expressing cells showed disruption of spheroid cell growth in three-dimensional acinar cultures in extracellular matrix, impaired wound healing and elevated migration on basement membranes in vitro [19] .
To investigate the underlying mRNA expression changes, we performed genome-wide transcription profiling on the cellular model used previously, i.e. MCF-10A cells expressing transfected c-Src(mt) or c-Src(wt) constructs [17] [18] [19] [20] . This cellular model allows for determining the effects of the single C-terminal point mutation in the c-Src protein by comparison with otherwise genetically identically cell lines. We show that c-Src(mt), but not c-Src(wt), significantly de-regulated the mRNA expression levels of 435 genes, herein referred as c-Src(mt) effector genes. These genes were characterized in terms of pathways and biological functions, allowing detailed insights into the mRNA expression profile induced by c-Src(mt). The respective gene products are mainly involved in migration and adhesion, as expected, but also in apoptosis and protein synthesis. An increased migratory potential of c-Src(mt)-expressing cells was suggested by the mRNA expression profile, and corroborated using an in vivo mouse model of lung tissue invasion, in line with our previous in vitro findings [17] [18] [19] [20] . Mining of the published scientific literature revealed that approximately 17.1% of the c-Src(mt) effector genes have not previously been linked to cellular migration. These include genes that are mainly involved in RNA transport and splicing processes. Comparison of the mRNA expression profile of c-Src(mt)-expressing cells with that of primary human cancer samples revealed significant overlap with 56 of 112 tumor samples, indicating similarities between c-Src(mt)-expressing cells and some cancer cells.
Results

Establishment of a c-Src(mt) cellular model
To study the effects of c-Src(mt), we used the human non-transformed epithelial MCF-10A cell line stably expressing c-Src(mt) or c-Src(wt) as a control [17] [18] [19] . The c-Src(mt) protein is identical to c-Src(wt) except for a single L?A substitution in the C-terminal GENL sequence. This hydrophobic motif mediates binding to PDZ domain-containing tumor suppressor proteins, and is shared by the ubiquitously expressed SFKs Src, Yes and Fyn, but not by Fgr, Hck, Lck, Lyn and Blk, which are expressed in non-adherent hematopoietic cells (Fig. 1A) . The c-Src protein contains an SH1 (kinase) domain, plus SH2 and SH3 domains (Fig. 1B) . The experimental approach comprised generation of stable cell lines with matched protein expression levels, RNA isolation, Illumina RNA sequencing (RNA-Seq), mapping of generated reads to the human genome using Bowtie [21] , quantification of transcript expression levels with the RNA-Seq by Expectation Maximization (RSEM) software [22] , determination of significantly differentially expressed mRNAs using DEseq [23] , and functional characterization of the respective gene products.
We stably transfected MCF-10A cells with the previously described constructs c-Src(wt) or c-Src(mt) [17] [18] [19] [20] , using lentiviral expression vectors (Fig. 1C) . Cells transfected with an otherwise identical expression vector but with a randomized nonsense sequence instead of c-Src are referred to as mock cells. Inclusion of the tetracycline-inducible system allowed for regulating transgene expression by addition of tetracycline (Tet) to the cell culture medium. Expression of the transgene in c-Src(wt)-and c-Src(mt)-transfected cells was verified by quantitative real-time PCR (qRT-PCR) (using the primers listed in Table 1 ) and Western blotting (Fig. 1D) . Only c-Src(mt)-expressing cells exhibited a transformed phenotype upon exposure to Tet, including a stretched morphology (Fig. 1E ), but no increased growth (data not shown). This is in accordance with our previous findings that expression of c-Src(mt) alters cellular morphology, but does not affect proliferation of these cells [19] . The RNA preparations displayed characteristic rRNA bands and no signs of degradation (Fig. 1F) . We selected RNA preparations obtained from cells exposed to 1 lgÁmL À1 Tet for whole-genome mRNA expression profiling, as the transgenes c-Src(wt) and c-Src(mt) were expressed at similar levels to endogenous c-Src (Fig. 1D) Gene expression levels were then quantified at the transcript level using RSEM [22] .
To assess the global changes in mRNA expression induced through the action of c-Src(wt) and c-Src(mt), transcript levels of both cell lines were compared to those of naive MCF-10A cells using DEseq [23] . Comparison of mock versus naive MCF-10A cells served as a negative control. The resulting logarithmic fold change values (logFC) for significantly differentially expressed mRNAs (q ≤ 0.05) were plotted as density graphs (Fig. 1G) . The profiles of mock and c-Src(wt) cells were almost identical, whereby the differences to naive MCF-10A cells may reflect non-specific effects of the lentiviral transfection procedure. The profile of cSrc(mt)-expressing cells was different, and showed more pronounced mRNA expression changes in both directions (down-and up-regulated genes), higher q values (Fig. 1H ) and a higher proportion of up-regulated genes (Fig. 1G) . The similar density graphs of mock-and c-Src(wt)-expressing cells suggest that c-Src (wt) is incapable of inducing detectable Src-specific mRNA expression changes. This is in accordance with previous studies where overexpression of the wild-type c-Src protein in mammalian cell lines did not cause major phenotypic alterations [17] [18] [19] [20] 24] .
To verify Src activity, we performed qRT-PCR expression analysis of six known Src targets: p53 (TP53) [25] and the related p63 (TP63), cyclin D2 (CCND2) [26] and mir-205 (MIR205HG) [27] , all of which are suppressed by Src, as well as matrix metalloproteinase 2 (MMP2) [28] and hyaluronan synthase 2 (HAS2) [29] that have been shown to be upregulated (Fig. 1I) . GAPDH served as a control, and, as expected, showed identical expression levels in all four cell lines. While the reported effects on all of the known Src target genes were verified at the mRNA and mock cells. This gave further support to the notion that expression of c-Src(wt) alone is insufficient to induce de-regulation of Src targets in our cellular model, but expression of c-Src(mt) did alter the transcript levels of these genes. This is in accordance with previous findings showing that either activating mutations [17] [18] [19] [20] 24] or co-factors [1] are required for increased Src activity. This may be because c-Src(wt) is maintained in an inactivated state through binding of PDZ domain-containing tumor suppressor proteins to its C-terminal GENL sequence (Fig. 1A) . In contrast, c-Src(mt), due to mutation of this motif, shows impaired binding to PDZ domains, rendering this mutant constitutively active [19] .
We next investigated effector mRNAs regulated by c-Src(mt). To account for possible Src-independent gene expression changes resulting from lentiviral transfection, we used comparison with mock cells instead of naive MCF-10A cells as a more stringent control. This comparison, c-Src(mt) versus mock, yielded a total of 435 significantly differentially expressed mRNAs (Table S1 ), whose respective genes are referred to as c-Src(mt) effector genes. This gene list contained all differentially expressed transcripts with q ≤ 0.05, irrespective of the fold change value. Of these, 51.5% (224 genes) were up-regulated in c-Src(mt)-expressing cells at the transcript level.
All known c-Src(mt) effector gene transcripts analyzed above by qRT-PCR also showed significant differential expression levels between c-Src(mt) and mock cells by RNA-Seq, except for TP53, probably because the corresponding expression levels were too similar (Table S1 and Fig. 1I ). mRNAs of three genes mentioned above, TP63, CCND2 and MIR205HG, exhibited negative logFC values, whereas those of MMP2 and HAS2 showed positive logFC values with statistical significance, confirming our qRT-PCR results as well as previous findings [26] [27] [28] [29] . As expected, GAPDH showed no altered mRNA expression, as also seen at the protein level (Fig. 1D ). Interestingly, the expression level of endogenous c-Src was not altered at the mRNA level (RNA-Seq) or at the protein level (Fig. 1D) . Therefore, any effects on mRNA expression levels were due to the activity of ectopically expressed c-Src(mt) and not endogenous c-Src, which was expressed at identical levels in all four cell lines. To further verify the RNASeq data, we performed qRT-PCR analysis for eight additional genes with significant mRNA de-regulation in the comparison of c-Src(mt) versus mock cells (Fig. 1I) . logFC values were determined using the 2 ÀDDCT method [30] and plotted against the logFC values obtained from RNA-Seq (Fig. 1J ). The strong correlation (R 2 = 0.983) verified the transcript levels inferred by RNA-Seq.
In summary, the c-Src(mt)-expressing cells exhibited alterations in mRNA expression levels that have previously been attributed to increased Src activity, and RNA-Seq data correlated well with the results of qRT-PCR expression analysis. The comparison of c-Src(mt) versus mock cells provided a comprehensive list of 435 c-Src(mt) effector genes for further characterization.
c-Src(mt) de-regulates genes involved in migration, apoptosis and protein synthesis
To obtain further insights into the mRNA expression program mediated by c-Src(mt), we subjected the set Table 1 . Primers used in this study.
Gene
Forward primer (5
of c-Src(mt) effector genes to bioinformatic analyses. First, characteristics of gene products were assessed by Gene Ontology (GO) category over-representation analysis [31] . Table S2 provides a complete list of GO terms for this analysis and the corresponding gene lists. Analysis of gene products in the GO category 'biological process' ( Fig. 2A) showed that c-Src(mt) effector genes play a prominent role in organelle organization (GO:0006996, q = 6.66 9 10 À6 ) ( Fig. 2A) , indicating changes in cellular morphology. This is in line with observations that c-Src(mt) promotes an invasive phenotype in epithelial cells and impaired cell polarization and cytoskeletal organization [17] [18] [19] [20] . Moreover, expression of c-Src(mt) significantly altered the mRNA expression levels of genes involved in cellular response to cytokine stimulation (GO:0034097, q = 1.31 9 10 À3 ). It has been noted that the cytokine profile in tumor microenvironments plays an important role in cellular migration [32] . For instance, c-Src (mt)-expressing cells over-express WNT5A mRNA (q = 9.28 9 10
À3
), whose gene product is a ligand of Frizzled receptors. Wnt/Frizzled signaling is known to be involved in cellular migration [33] . Transcripts of apoptosis-associated genes were also de-regulated in c-Src(mt)-expressing cells (GO:0006915, q = 1.31 9 10 À3 ). Evasion of apoptosis is recognized as a hallmark of cancer, and Src is known to play a key role in this process [1] . Gene products of c-Src(mt) effector genes are mainly localized in the cytosol and nucleus ( Fig. 2A , 'cellular component'), perhaps reflecting a predominant involvement in cytosolic signaling and gene regulation processes. An enrichment of proteins binding to structural proteins such as actin (GO:0003779, q = 5.33 9 10 À4 ) suggests that c-Src(mt)
effector genes are involved in cytoskeleton remodeling and migration ( Fig. 2A , 'molecular function').
To further characterize the roles of c-Src(mt) effector genes, we performed pathway enrichment analysis using ConsensusPathDB [34] . We found that c-Src(mt) effector genes mainly affect pathways involved in cell migration and adhesion (Fig. 2B, yellow) , including hemidesmosome assembly and integrin pathways, as well as protein synthesis (Fig. 2B , blue) and apoptosis ( Fig. 2B, red) .
c-Src(mt) effector genes involved in cellular migration and adhesion included the integrin receptor component genes ITGA2, ITGA6 and ITGAV, all of which were transcriptionally down-regulated (Fig. 2C) . Integrin receptors are known to attach cells to the extracellular matrix (ECM) by binding to ECM components such as laminin, collagen, fibronectin and E-cadherin, and their de-regulation promotes invasiveness. For instance, ITGAV expression has been linked with metastatic activity in colorectal cancer [35] , and ITGA2 genetic variants may be associated with invasiveness of gastric cancer [36] . In addition, a number of components of the ECM itself were de-regulated at the mRNA level by the action of c-Src(mt). These include decorin (DCN), fibronectin 1 (FN1), fibrillin 1 (FBN1), which are up-regulated, and E-cadherin (CDH1), which is downregulated. Various mRNAs encoding collagen chain components were either up-(COL8A1, COL12A1 and COL28A1) or down-regulated (COL17A1). Of note, over-expression of decorin [37] , fibronectin 1 [38] and collagen chains COL8A1 [39] and COL12A1 [40] has recently been shown to promote invasiveness of various cancer types. These results indicate that c-Src(mt) significantly alters cell-matrix interactions, thereby decreasing cell adhesion and promoting cellular migration and invasiveness. Moreover, MMP2, an enzyme that degrades type IV collagen, the major constituent of basement membranes, was transcriptionally up-regulated by c-Src(mt). Increased expression of MMP2 has been shown to correlate with cellular invasion [1] . Except for the collagen chain COL8A1 and fibronectin 1, none of the above mentioned genes involved in cell adhesion were de-regulated by c-Src(wt) at the mRNA level (Fig. 2C) , further confirming that the activating mutation of c-Src(mt) promotes Src activity.
c-Src(mt) effector genes involved in apoptosis signaling include those involved in maintaining cytoskeleton integrity, such as adducin 1 (ADD1) and plectin (PLEC), both of which were transcriptionally upregulated by c-Src(mt) (Fig. 2C) . Adducins are components that are important for the cortical cytoskeleton network, and are subject to caspase-3-mediated cleavage during cisplatin-mediated apoptosis [41] . Plectin serves as a cross-linking molecule for the cytoplasmic filament system, and is thus involved in maintaining cytoskeleton integrity, and its cleavage by caspase-8 occurs early during tumor necrosis factor receptor-mediated apoptosis [42] . Up-regulation of cytoskeletal components such as adducin 1 and plectin by c-Src(mt) may thus interfere with caspase-mediated cytoskeleton instability, thereby suppressing apoptosis. While ADD1 transcripts were not de-regulated by c-Src(wt), PLEC mRNA was upregulated, but less markedly than by c-Src(mt) (Fig. 2C) . We verified the expression of selected ECM and cytoskeletal proteins by immunohistochemistry (see below).
While the involvement of Src in cell adhesion and apoptosis is well-known [1], we also observed overrepresentation of c-Src(mt) effector genes in a surprisingly large number of pathways involved in translation and protein synthesis (Fig. 2B) . These include various steps of protein synthesis, such as mRNA transport and degradation, and translation initiation, as well as amino acid biosynthesis and transport (Table S3) . A number of transcripts of eukaryotic translation initiation factors (EIFs), including EIF3A, EIF3E, EIF4A2 and EIF4G1, and other proteins involved in translation initiation were up-regulated by c-Src(mt) (Fig. 2C) . mRNAs for the small and large subunit ribosomal proteins RPL29, RPL31 and RPS24 were also upregulated. Amino acid transport across the cell membrane may have been influenced by c-Src(mt), as a number of mRNAs for genes encoding amino acidtransporting solute carrier proteins, such as SLC1A5, SLC3A2, SLC7A2, SLC7A5 and SLC38A1, were de-regulated. In addition, mRNAs of amino acid biosynthesis genes were de-regulated by c-Src(mt), including down-regulation of transcripts of serine hydroxymethyltransferases 1 and 2 (SHMT1/2), enzymes that catalyze the conversion of serine to glycine, and down-regulation of the mRNA for the glycine dehydrogenase (decarboxylating) gene GLDC, whose gene product degrades glycine. We hypothesize that c-Src(mt) stimulates global protein synthesis by increasing the number of ribosomes and the intracellular levels of translation initiation factors and free amino acids. Moreover, genes involved in mRNA decay, such as the CNOT6 cytoplasmic deadenylase, were transcriptionally down-regulated by c-Src(mt), while the polyadenylate-binding protein 1 (PABPC1) gene, which is essential for translation initiation, was up-regulated at the mRNA level. Moreover, the overall higher proportion of up-regulated transcripts compared to down-regulated transcripts in c-Src(mt)-expressing cells indicated an elevated pool of available mRNAs, further increasing protein expression, including that of pro-invasion and anti-apoptosis genes ( Fig. 2A-C) . Only a few of the above-mentioned mRNAs involved in protein synthesis were deregulated by c-Src(wt) (Fig. 2C) . We conclude that activation of protein synthesis-related transcripts required the constitutively active form of c-Src.
In summary, over-expression of c-Src(mt) was sufficient to modulate transcription of genes involved in cell migration/adhesion, apoptosis and protein synthesis. In particular, de-regulation of mRNAs whose gene products are involved in integrin signaling, ECM remodeling, composition of the cytoskeleton, and the translation machinery was observed.
Non-migration-associated c-Src(mt) effector genes are involved in mRNA splicing
The role of activated c-Src in promoting metastasis is well-known [1] . However, the transcriptome data presented here also revealed a prominent effect of c-Src (mt) expression on protein synthesis (Fig. 2B) . To identify c-Src(mt) effectors that are not associated with metastasis, we mined PubMed abstracts, using a defined lexicon of terms associated with migration. The majority of c-Src(mt) effector genes, 415 of 435 (95.4%), were referred to in PubMed abstracts. Of these, 344 (82.9%) were linked to migration, which may reflect that previous studies investigating Src activity were biased towards assessment of its migration-promoting activity. On the other hand, 71 genes (17.1%) were not linked to migration (highlighted in green in Table S1 ). These 71 genes are of particular interest as they may include genes that have not previously been associated with Src activity. To obtain an insight into the role of these 71 genes, they were subjected to Gene Ontology (GO) category over-representation analysis. Interestingly, these genes appeared to be mainly involved in splicing of pre-mRNAs (GO:0005689, 'U12-type spliceosomal complex'; GO:0071013, 'catalytic step 2 spliceosome', both q = 3.62 9 10 À2 ) ( Table S4) . De-regulated splicing is a known feature of transformed cells [43] . Our data so far suggests that the constitutively active c-Src(mt) mutant, in addition to promoting metastasis, may have an effect on protein synthesis and splicing. To our knowledge, these functions have not previously been attributed to Src. 3%) showed significant overlap with c-Src(mt) effector genes (q ≤ 0.05) (Fig. 3A, left) . This was the case for most breast cancer (4/6), leukemia (5/6), ovarian (5/7), prostate (7/13) and renal cancer samples (3/5), as well as all liver cancer samples (4/4). Increased Src activity has been identified in breast, ovarian and liver cancers and leukemia [45] , as well as prostate cancer [46] and renal cancer [47] . Analysis of ONCOMINE datasets for cancer progression (metastatic versus localized, n = 42) revealed that 18 (42.9%) showed significant overlap with c-Src(mt) effector genes (Fig. 3A, right) , including most of the lung cancer samples (4/5) and the prostate cancer samples (9/16). Increased Src activity has been shown to be associated with increased metastasis in lung [45] and prostate cancer [48] . Therefore, c-Src (mt)-expressing cells are a valid, albeit simplified, model for some human cancers and their progression to metastasis. These results suggest that the single amino acid mutation in c-Src(mt) does indeed affect similar transcripts to those that are found to be dysregulated in diverse tumor or metastatic cells.
c-
We next sought to investigate whether the nonmigration-associated c-Src(mt) effector genes (Table S1 ) are associated with human cancer. Therefore, we searched the ONCOMINE database for any evidence of their de-regulation in normal tissue versus cancer pairs. We identified 18 genes that showed significant transcriptional up-regulation (eight genes) or down-regulation (ten genes) (q ≤ 0.05) in at least half of the analyzed datasets of the respective cancer types (Fig. 3B) . All of these genes showed similar behavior in the c-Src(mt) cells (over-or underexpressed with q ≤ 0.05 compared to mock cells). Of note, most of these genes were de-regulated in leukemia samples. Thus, the non-migration-associated c-Src (mt) effector genes are probably most relevant for this cancer type.
Discussion
Here we have analyzed a cellular model of C-terminally mutated constitutively active Src kinase that was obtained by stable expression of c-Src(mt) at physiological levels in non-transformed human cells. The c-Src (mt)-specific transcriptional changes inferred by RNA sequencing were in good agreement with qRT-PCR measurements (Fig. 1I,J) . The substantial changes in cellular morphology induced by expression of c-Src (mt) (Fig. 1E) indicated alterations in the expression levels of functionally active proteins. Despite these findings, mRNA expression changes may not necessarily be reflected at the protein level for every identified gene. However, recent studies demonstrated good correlations between mRNA and protein levels in differential gene expression analyses, suggesting that quantifying mRNA may be more useful than previously acknowledged [49, 50] . It should be noted that mRNA turnover may be influenced by c-Src(mt), as suggested by altered transcription of genes involved in mRNA decay (e.g. CNOT6) and translation initiation (e.g. PABPC1). Altered turnover, in addition to mRNA levels per se, may further influence protein expression of c-Src(mt) effector genes.
The expression of c-Src(mt), but not of c-Src(wt) at comparable levels (Fig. 1D) , altered the mRNA levels of previously reported Src targets (Fig. 1I) . This is in accordance with previous findings that activation of c-Src, either by activating mutations or deletions in the C-terminus [17] [18] [19] [20] 24] , or via the action of co-factors, such as FAK [1] , is required for its transforming activity. Here, whole-genome transcriptome analysis revealed that most of the 435 genes de-regulated by c-Src(mt) at the mRNA level are implicated in migration and adhesion, apoptosis and protein synthesis ( Fig. 2A-C) .
Elevated Src activity frequently correlates with increased tissue invasion [45] . The change in mRNA levels of migration/adhesion-associated genes in the c-Src(mt)-expressing cells (Fig. 2B,C) suggested that these cells may also show increased metastatic potential. To test whether c-Src(mt)-expressing cells exhibit increased capacity to metastasize in vivo, we used an established mouse model of metastatic lung tissue invasion [51] . Eight-week-old SCID mice were intravenously injected with 9 9 10 5 naive MCF-10A, c-Src(wt), c-Src (mt) or mock cell lines. To induce transgene expression in the engineered cell lines, 1 lgÁmL À1 Tet was added to the drinking water of all animals. Mice were sacrificed after 42 days, and the phenotypes of lung tissues were analyzed (Fig. 4A) . Macroscopic analysis revealed visible lung metastases only in those mice that received c-Src(mt)-expressing cells, indicating that expression of c-Src(mt) predisposes tumor cells to extravasate and migrate into epithelial tissue. Lung metastases were found in two of five mice injected intravenously with cSrc(mt)-expressing cells, but were absent in the lungs of (Fig. 4B) . Representative histological haematoxylin/eosin-stained sections are shown in Fig. 4C . The difference in metastasis formation in c-Src(mt)-expressing cells compared with mock-expressing cells was not statistically significant (P = 0.1). More extensive studies and larger sample sizes are required to corroborate this initial data. The observed trend in vivo is in accordance with previous findings showing that this c-Src mutant promoted motility in in vitro migration assays [19] . In contrast, over-expression of the wild-type c-Src protein alone has been shown to cause only minimal changes in migratory activity [19, 29, 54] . Accordingly, we observed no metastases in mice that received c-Src(wt)-expressing cells (Fig. 4B,C) . The lung metastases were subjected to immunohistochemical staining to qualtitatively verify the in vivo expression of c-Src(mt) effector genes at the protein level. We used four proteins whose mRNAs were significantly up-regulated by c-Src(mt); the ECM components fibronectin 1 and matrix metalloproteinase 2 (FN1 and MMP2 genes), and the cytoskeletal proteins adducin 1 and plectin (ADD1 and PLEC genes) (Fig. 5 ). In addition, we investigated the expression of Ser235/265-phosphorylated S6 ribosomal protein, a marker of elevated protein synthesis [55] . The results confirmed that adducin 1, MMP2, plectin and Ser235/ 265-phosphorylated S6 ribosomal protein were expressed in the metastatic cells. Expression of fibronectin 1 appeared to be restricted to the border of the metastases.
Literature mining revealed that more than 82.9% of c-Src(mt) effector genes have previously been linked to cellular migration. The remaining 17.1% of genes showed an enrichment of genes involved in mRNA splicing (Table S4) , a post-transcriptional process required for translation. Interestingly, various cellular pathways relevant for protein synthesis showed enrichment of genes that were transcriptionally de-regulated by c-Src(mt) (Fig. 2B) . Moreover, immunohistochemistry revealed the expression of phosphorylated S6 ribosomal protein, a marker of increased translation [55] , in c-Src(mt)-expressing cells (Fig. 5) . To our knowledge, de-regulation of protein synthesis has not yet been linked with Src activity, perhaps because most previous studies mainly focused on investigating its metastasis-promoting potential.
Therefore, we suggest that Src activity is associated with an increase in global protein synthesis. Interestingly, this function has recently been attributed to another proto-oncogene product, c-Myc [56] . The importance of protein synthesis in cancer development has been neglected historically [56] . However, recent evidence underlines the importance of de-regulated translation in various cellular processes, including cancer progression. Using ribosomal profiling, Hsieh et al. [57] have shown that oncogenic signaling of the mammalian target of rapamycin (mTOR) kinase heavily influences the translational machinery, and thereby cancer invasion and metastasis, through increased translation of pro-invasion mRNAs. Consequently, components of the translational machinery, such as the translation initiation factor eIF4E, are now being explored as therapeutic targets to treat cancer [56] . In line with these findings, we found that Src activity caused de-regulation of various steps of translational control. Proteins whose mRNAs were up-regulated by c-Src(mt) included translation initiation factors, ribosomal proteins and proteins implicated in mRNA stability, thereby potentially promoting the 'cancerous' translation machinery. Interestingly, Src is known to phosphorylate and hence activate phosphoinositide 3-kinase, whose downstream targets include mTOR [56] . mTOR stimulates protein synthesis by phosphorylating eIF4E-binding protein 1 and ribosomal protein S6 kinase 1/2 (S6K1/2). We therefore propose a dual mechanism of translational activation by Src, through cytosolic activation of the mTOR pathway and transcriptional activation of components of the translational machinery, as shown in this study. This may lead to increased translation of pro-invasive and antiapoptotic mRNAs, thus potentially promoting cellular migration.
A potential target for cancer therapies is FAK, a cytoplasmic tyrosine kinase that is a key downstream signal transducer of integrin receptors [58, 59] . FAK is directly phosphorylated by Src kinase, leading to activation of multiple intracellular signaling pathways that are relevant for apoptosis and cell migration, amongst others [59] . FAK and Src kinase synergize in promoting cell migration and invasion [60, 61] . We have recently shown that the expression of c-Src(mt) leads to increased levels of phosphorylated FAK in MCF-10A cells, concomitant with elevated cell motility [19] . The transcriptome analysis in the present study revealed that the mRNA expression level of FAK was not significantly influenced by c-Src(mt), as FAK (PTK2, protein tyrosine kinase 2) was not among the c-Src(mt) effector genes (Table S1 ). Together with our previous findings [19] , the results here indicate that FAK activation by c-Src(mt) mainly involves its Srcdependent phosphorylation but transcription levels remain unaltered. Of note, both up-regulation and increased phosphorylation of FAK have been detected in numerous human metastatic tumors compared to benign, non-metastatic tumors or normal tissues [59] . The over-expression of FAK in various human neoplastic diseases, such as invasive colorectal carcinoma or esophageal squamous cell carcinoma [59] , may be caused by Src kinase-independent mechanisms. Increased FAK phosphorylation has been identified in primary breast cancer specimens and breast cancer cell lines compared to normal tissue, which may be a direct consequence of Src kinase activity [62, 63] .
In line with these findings, the mRNA expression changes induced by c-Src(mt) showed significant similarities with transcription profiles of many primary human cancers, especially breast cancer, leukemia, ovarian, prostate and renal cancers (Fig. 3A) . We observed significant overlap with mRNA profiles of some colon cancers (three of six comparisons of normal tissue versus cancer and one of three comparisons of metastatic versus localized), for which activating C-terminal mutations of the c-Src gene have been reported previously [24] . Thus, c-Src(mt)-expressing cells not only exert increased migratory potential, but also show a transcription signature with similarities to some primary tumors that may not yet have progressed to metastatic behavior. It should be noted that tumorigenesis and progression to metastasis in vivo is a multi-step process that involves inactivation of tumor suppressor genes and acquisition of oncogenic mutations [64, 65] . While the cellular model studied herein certainly does not reflect the complex mechanisms of tumorigenesis in vivo, it provides insights into Src-dependent progression to metastasis.
Previous genome-wide analyses of the effect of Src activity on gene transcription include microarray analyses of v-Src-transformed mouse cells [3, 66] or RSV-transformed chicken cells [67, 68] . One previous study analyzed the gene transcription profile of MCF-10A cells transformed with ER-Src, a derivative of v-Src that is fused to the ligand-binding domain of the estrogen receptor [7] . In contrast, the cellular model described herein reduces the induction of metastatic behavior to a single point mutation in the c-Src protein resulting in loss of binding to tumor suppressors, leading to increased kinase activity. This may explain why there is little agreement between the c-Src(mt) effector genes identified in this study and the v-Src-regulated genes identified by others [3, 7, [66] [67] [68] . Interactions with PDZ domaincontaining tumor suppressor proteins not only influence the kinase activity of c-Src, but also its intracellular localization [17] . It would therefore be interesting to compare c-Src(mt) to other activated Src mutants, for instance substituted at tyrosine residue 529 (Fig. 1B) but with an intact C-terminal GENL peptide. This may reveal which effects are directly attributed to interactions with PDZ domaincontaining proteins.
We identified 71 c-Src(mt) effector genes that have not been previously associated with metastasis, which were mainly involved in mRNA splicing, and thus influence protein synthesis (Table S4 ). A number of these genes also showed transcriptional de-regulation in human primary cancer samples, especially in leukemia (Fig. 3B) . SFK members such as Fgr or Hck that, similar to c-Src(mt), do not bind to PDZ proteins, are mainly present in non-adherent hematopoietic cells including leukocytes [17] . This may explain why we observed such a high degree of overlap between transcriptional signatures of leukemic and c-Src(mt)-expressing cells.
One way by which c-Src(mt) may alter transcription levels is by activating specific transcription factors (TFs). To investigate this, we identified DNA sequence motifs that were enriched within the promoter regions of c-Src(mt) effector genes, using the Amadeus motif discovery platform [69] . A number of these motifs showed overlap with known binding sites of 17 human TFs (Fig. 6) [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] . These TFs may be directly or indirectly activated by c-Src(mt), thereby contributing to the mRNA expression profile observed in c-Src(mt)- expressing cells. For instance, one of the identified TFs, the signal transducer and activator of transcription 3 (STAT3), has been previously identified as a downstream target of c-Src [1] . DNA binding of STAT3 is activated in Src kinase-transformed cells through tyrosine phosphorylation [85] . Similarly, STAT5A may be activated by Src kinase [86] . Moreover, Src signaling has been shown to regulate the activity of the TF p300 that shows histone acetyltransferase activity, thereby contributing to epigenetic gene regulation [87] . Src kinase positively regulates the histone acetyltransferase activity of p300, and thereby its ability to increase the transcription of target genes [87] . Of note, neither the three TFs mentioned nor the other identified TFs were differentially expressed in c-Src(mt)-expressing cells (Fig. 6 and Table S1 ). This indicates that their activity was probably altered through post-translational modifications involving c-Src(mt), or increased mRNA turnover.
Overall, this study provides detailed insights into the transcriptional program induced by a specific C-terminally mutated form of c-Src kinase, c-Src(mt), which is impaired in binding to tumor suppressors. Cells expressing this mutant extravasated and migrated into lung tissue of mice in vivo to form metastases. We identified a number of c-Src(mt)-regulated genes that have no yet been associated with metastatic behavior. They may deserve further investigation as putative biomarkers of invasive cells or as targets of therapeutic approaches, especially in the context of Src-driven progression to metastasis.
Experimental procedures
Ethics statement
Animals were maintained under specific pathogen-free conditions. All experiments and procedures involving animals were approved by the Cantonal Veterinary Authority of Zurich, in accordance with the guidelines of the Swiss Animal Protection Law, which strictly follows the principles declared in the Basel Declaration, namely that research in animals is performed according to the recommendations of the International Council for Laboratory Animal Science. All expression data for human tumors and tissues analyzed in this study were retrieved from the ONCOMINE public domain database [44] . hydrocortisone (all SigmaAldrich) plus 5% horse serum (Gibco). Cells were maintained at 37°C with 5% CO 2 .
Lentiviral constructs
The hemagglutinin-tagged Src constructs have been described elsewhere [17] [18] [19] . The lentiviral particles for Tetinducible expression of c-Src(wt) (LVP-Src-wt) and c-Src (mt) (LVP-Src-mt), as well that encoding as a short nonsense construct (LVP-mock), conferred resistance to Blasticidin S. The construct LVP017-Neo allows constitutive expression of TetR and confers resistance to G418 (Fig. 1C) . Lentiviral particles were prepared by AMS Biotechnology (Abingdon, UK). Sequences were confirmed by capillary sequencing.
Generation of stably expressing cells
MCF-10A cells were grown to 50% confluence in complete growth medium. Cells were incubated with LVP017-Neo (multiplicity of infection = 10) and lentiviral expression particles (multiplicity of infection = 3) for 72 h. Then the medium was replaced with fresh complete growth medium containing 60 lgÁmL À1 G418 (Gibco) and 3.5 lgÁmL
À1
Blasticidin S (Bsd) (Invitrogen, Carlsbad, CA, USA) for 14 days to select doubly positive cells. Non-transfected control cells were killed within 14 days when exposed to either 60 lgÁmL À1 G418 or 3.5 lgÁmL (Fig. 1D) .
Preparation of total RNA
Cells were grown to approximately 70% confluence in complete medium supplemented with 30 lgÁmL À1 G418 and 1.75 lgÁmL À1 Bsd. Tetracycline (Sigma-Aldrich) was added to the culture medium, and cells were incubated for 24 h. Then total RNA was extracted using Trizol (Invitrogen) according to the manufacturer's instructions. The RNA was precipitated at À80°C and pelleted by centrifugation at 12 000 g for 10 min. The pellets were washed with 75% ethanol, air-dried, and solubilized in nuclease-free water. Remaining DNA was removed using an RNase-free DNase set (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Then the solution was subjected to phenol/chloroform extraction. RNA integrity was assessed by gel electrophoresis using 300 ng total RNA per lane in a 19 TAE gel containing 1% w/v agarose. The gel was run at 130 V for 45 min, and stained with ethidium bromide. The GeneRuler 1 kb DNA ladder (Fermentas, Waltham, MA, USA) was used as a size marker.
Primer design and synthesis
Primers for qRT-PCR were designed such that PCR products were smaller than 300 bp and were intron-spanning, using the primer3 program (http://primer3.wi.mit.edu) [88] and cDNA sequences retrieved from the UCSC Genome Browser (https://genome.ucsc.edu) and the current release of the human genome [89] . The GAPDH primer pair has been described previously [90] . The forward primer mu SRC_HA is situated within the hemagglutinin tag of the cSrc constructs to avoid amplification of endogenous c-Src expressed by MCF-10A cells. Primers were synthesized by Metabion (Martinsried, Germany). Table 1 provides a complete list of primer sequences used in this study.
Quantitative real-time PCR
Total RNA preparations were reverse-transcribed using a highcapacity cDNA reverse transcription kit (Applied Biosciences, Foster City, CA, USA) according to the manufacturer's instructions. Reverse transcription products were quantified using Fast SYBR Green Master Mix (Applied Biosystems) on an Applied Biosystems 7900HT fast real-time PCR system. Cycle conditions were: 10 min incubation at 95°C, followed by 50 amplification cycles of 95°C for 15 s and 58°C for 1 min.
Western blotting
Cells were resuspended in buffer A (10 mM HEPES, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 1 mM dithiothreitol, protease inhibitor cocktail) and lyzed mechanically. After centrifugation for 5 min at 2500 g, the pellet was subjected to DNase I digestion in 10 mM HEPES, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.2U DNase I, 1 mM dithiothreitol, protease inhibitor cocktail, and centrifuged as described above. The resulting supernatant was combined with the first one, and the total protein concentration was determined using 
Sequence read alignment
The Illumina paired-end sequence reads were mapped to the University of California Santa Cruz hg19 human reference genome (http://hgdownload.cse.ucsc.edu/goldenPath/ hg19/database/) using the Bowtie read aligner (0.12.8 release, default parameters) [21] .
Gene expression and determination of differential expression
Gene expression was measured in non-transfected cells (naive MCF-10A), cells transfected with the mock lentiviral vector, cells transfected with the c-Src(wt) lentiviral vector and cells transfected with the c-Src(mt) lentiviral vector using Illumina RNA-Seq technology. RNA expression levels were determined using a standardized analysis pipeline based on RSEM (RNA-Seq by expectation maximization) [22] and DESeq (differential expression of RNA-Seq data) [23] . RSEM version 1.1.20 was used to quantify transcripts from RNA-Seq using the following parameters for 'rsem-preparereference': reference genome hg19; annotation Ensembl 67; polyA length 15; Bowtie version 0.12.8. The following parameters were used for 'rsem-calculate-expression': calculate 95% credibility intervals; paired-end reads. The retrieved transcript count data were then fed into DESeq, which normalizes the count data between samples and calculates expression fold changes (FC) as well as P values and adjusted P values to determine differential expression of transcripts between two samples (cell lines). The default settings were used for normalization and variance estimation: estimateSizeFactors(cds) and estimateVarianceFunctions(cds), respectively. Differential expression between cell lines A and B was tested using nbinomTest(cds, 'cell line A', 'cell line B').
Corresponding genes with a false discovery rate-adjusted q value ≤ 0.05 for their fold change were considered differentially expressed. For any given gene of the comparison between cell line A and cell line B, if transcripts were detect-able in A but not detectable in B, the reported FC value is 'Inf'; if transcripts were detectable in B but not detectable in A, the reported FC value is '-Inf'.
Gene Ontology over-representation
The ConsensusPathDB [34] was used to identify predominantly occurring GO terms among the candidate genes in order to determine functional commonalities between them. P values were derived from a Fisher's exact test performed for the candidate genes against the background set of all genes in the human genome. Correction for multiple testing was performed using the false discovery rate method [92] , to calculate q values.
Pathway over-representation
Over-represented pathways involving the candidate genes were identified using ConsensusPathDB (release 25) [34] , a pathway database that currently integrates interaction data from 31 public resources. P and q values were calculated as for the above GO analysis.
Mouse experiments
For the tumor growth studies, severe combined immunedeficient (SCID) mice were obtained from Charles River Laboratories (Wilmington, MA, USA). Eight-week-old female mice were intravenously injected with 9 9 10 
Immunohistochemistry
Lung tissues were fixed with 4% paraformaldehyde and embedded in paraffin. Paraffin sections (2 lm) were either stained with hematoxylin/eosin or by automated immunohistochemistry staining using rabbit anti-MMP2 (Abcam, Cambridge, UK), rabbit anti-fibronectin (Abcam), mouse anti-a-adducin (Abcam), rabbit anti-plectin (Abcam), rabbit anti-phospho-S6 ribosomal protein (Ser235/236) (Cell Signaling Technology, Danvers, MA, USA), and polymeric horseradish peroxidase (Poly-HRP)-conjugated anti-Rabbit IgG and anti-Mouse IgG (Leica, Wetzlar, Germany) for detection. Image acquisition was performed using DotSlide BX51 (Olympus, Tokyo, Japan), SCN400 (Leica), Axio Z1 (Zeiss, Oberkochen, Germany) or BX53 (Olympus) microscopes.
Literature mining
We aimed to find genes that may be associated with cellular migration but have so far not been reported in this context. Thus, we used an automated literature mining approach to scan PubMed abstracts for information on the candidate genes with respect to migration. For that purpose, we defined a lexicon of migration-related terms (migration, metastasis, pseudopodia, wound healing, adherence, adhesion, homing, pathfinding, motility, angiogenesis, invasion, cancer progression, PDZ domain, cytoskeleton), and searched for co-occurrence of the gene names with those terms. We used an evidence score defined as s ij ¼ log 2 ðP ij =ðP i P j ÞÞ to quantify literature evidence for a gene, where P ij is the frequency of co-occurrence of the lexicon term i and the gene j, and P i and P j are their marginal frequencies. The evidence score for each gene was computed as the sum of co-associations over the entire lexicon:
A high score indicates that a gene has often been related to metastasis and other terms of the lexicon. Genes with low or negative evidence scores were therefore selected for further analysis. Seventy-one genes showed no evidence.
Cancer gene expression profiles
Gene set enrichment analysis was performed using publicly available cancer gene expression datasets from the ONCO-MINE database [44] . We looked for cancer datasets that showed similar expression profiles to our c-Src(mt)-expressing cells versus mock cells, focusing on studies that compared different stages of cancer tissue, i.e. sets with the prefix NC for 'normal tissue versus cancer' and CP for 'cancer progression versus primary tumor' (referred to as 'metastatic versus localized tumor' throughout the manuscript). At the time of writing, 112 such datasets were available, all of which were considered. To calculate the significance of overlap of c-Src(mt) effector genes with the gene sets from the ONCOMINE database, we performed Fisher's exact tests and corrected for multiple testing using the false discovery rate method.
Identification of transcription factor binding sites
DNA sequence motifs that are enriched in the promoter regions of c-Src(mt) effector genes were determined using the Amadeus platform [69] . Standard parameters were used, with motif lengths of 8-12 bp and the hg19 release of the human genome (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/). The output from Amadeus is shown in Fig. S1 . Human transcription factor binding sites from TRANSFAC [93] that showed similarity to the identified motifs were chosen for further investigation. The respective position-specific weight matrices were retrieved from theCistrome database at cistrome.dfci.harvard.edu [94] . Sequence logos were computed from position-specific weight matrices using WebLogo3 at weblogo.threeplusone.com [95] 
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